The OSM-JAK-STAT pathway has been implicated in progression of several cancers, including NSCLC; treatment of NSCLC cells with filgotinib resulted in inhibition of STAT3 activation and reduced OSM receptor expression[50]. Here, OSM is linked to cancer.